A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age (NCT06855160)
A Phase 3a, Open-Label, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Varicella Vaccine and Priorix Compared With Subcutaneous Administration of Varivax and Priorix, When Given as a First Dose to Healthy Children 12 to 15 Months of Age
🩺 Plain-English Summary (8th-Grade Level)
This study aims to assess the immune response and safety of GSK's candidate chickenpox and marketed MMR vaccines when given to children 12 to 15 months of age via a muscle injection. It compares the GSK vaccines to Merck's chickenpox vaccine, administered just under the skin. Additionally, the study will evaluate the immune response and safety of giving the GSK vaccines along with other childhood vaccines through a muscle injection.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Tucson, Arizona
Age range: 12 Months to 15 Months
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (22 Sites)
- GSK Investigational Site — Tucson, Arizona
- GSK Investigational Site — Huntington Park, California
- GSK Investigational Site — Sherman Oaks, California
- GSK Investigational Site — Coral Gables, Florida
- GSK Investigational Site — Miami Lakes, Florida
- GSK Investigational Site — Tampa, Florida
- GSK Investigational Site — Idaho Falls, Idaho
- GSK Investigational Site — Dayton, Ohio
- GSK Investigational Site — Houston, Texas
- GSK Investigational Site — Lewisville, Texas
- GSK Investigational Site — Mansfield, Texas
- GSK Investigational Site — Pharr, Texas
- GSK Investigational Site — Richmond, Virginia
- GSK Investigational Site — Alken,
- GSK Investigational Site — Tartu,
- GSK Investigational Site — Athens,
- GSK Investigational Site — Athens,
- GSK Investigational Site — Thessaloniki,
- GSK Investigational Site — Trzebnica,
- GSK Investigational Site — Brasov,
- GSK Investigational Site — Calarasi,
- GSK Investigational Site — Chiang Mai,
📞 Contact the Study Coordinator
Phone: (877) 379-3718
Email: GSKClinicalSupportHD@gsk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chickenpox
- A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age — Phoenix, Arizona
- A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age — Salvaleón de Higüey, La Altagracia Province
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age — Mobile, Alabama
Explore by condition: All Chickenpox clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.